Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aztreonam: the first monobactam.

R B Sykes, D P Bonner

    The American Journal of Medicine
    |February 8, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Monobactams, initially poor antibiotics, were developed into aztreonam, a potent agent against aerobic gram-negative bacteria. Aztreonam offers targeted therapy with fewer side effects than broad-spectrum antibiotics.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Synergistic activity of the novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species.

    International journal of antimicrobial agents·2002
    Same author

    Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.

    International journal of antimicrobial agents·2001
    Same author

    From moulds to drugs.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2001
    Same author

    Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents.

    International journal of antimicrobial agents·2001
    Same author

    Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

    Antimicrobial agents and chemotherapy·2000
    Same author

    Comparative killing rates of fluoroquinolones and cell wall-active agents.

    Antimicrobial agents and chemotherapy·2000
    Same journal

    Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

    The American journal of medicine·2026
    Same journal

    GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

    The American journal of medicine·2026
    Same journal

    Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

    The American journal of medicine·2026
    Same journal

    Cave Canem - Beware of the Dog.

    The American journal of medicine·2026
    Same journal

    Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

    The American journal of medicine·2026
    Same journal

    Mesenteric panniculitis.

    The American journal of medicine·2026
    See all related articles

    Area of Science:

    • Microbiology
    • Medicinal Chemistry
    • Pharmacology

    Background:

    • Monobactams are unique, bacterially produced monocyclic beta-lactam antibiotics.
    • Early monobactams had poor antibacterial activity but interacted with bacterial cell wall synthesis.
    • Development focused on enhancing beta-lactam binding activity.

    Purpose of the Study:

    • To develop clinically useful monobactam antibiotics.
    • To create a compound effective against aerobic gram-negative bacteria.
    • To achieve resistance to bacterial beta-lactamase enzymes.

    Main Methods:

    • Novel screening procedures for antibiotic isolation.
    • Chemical modification to enhance beta-lactam binding.
    • In vitro and in vivo efficacy testing against various bacterial strains.

    Related Experiment Videos

    Main Results:

    • Aztreonam emerged as a highly effective antibiotic against aerobic gram-negative bacteria.
    • Aztreonam exhibits high resistance to various beta-lactamases, including plasmid-mediated types.
    • Unlike other antibiotics, aztreonam does not induce chromosomally mediated beta-lactamases.

    Conclusions:

    • Aztreonam provides targeted therapy against aerobic gram-negative pathogens.
    • Its narrow spectrum minimizes disruption of gut flora, reducing side effects.
    • Aztreonam offers a valuable alternative to broad-spectrum antibiotics, with potential for combination therapy.